Protection against Staphylococcus aureus by antibody to the polyglycerolphosphate backbone of heterologous lipoteichoic acid

Journal of Infectious Diseases

Volumn 205, Issue 7, 2012, Pages 1076-1085

  Theilacker, Christian ^a   Kropec, Andrea ^a   Hammer, Felix ^a   Sava, Irina ^a   Wobser, Dominique ^a   Sakinc, Tuerkan ^a   Codée, Jeroen D C ^b   Hogendorf, Wouter F J ^b   Van Der Marel, Gijsbert A ^b   Huebner, Johannes ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b LEIDEN UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

LIPOTEICHOIC ACID; OLIGOMER; RABBIT ANTISERUM; TEICHOIC ACID; TYPE 1 LIPOTEICHOIC ACID; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN BINDING; ARTICLE; BACTERIAL CLEARANCE; BACTERIAL PERITONITIS; BACTERIAL STRAIN; CONTROLLED STUDY; CROSS REACTION; ENTEROCOCCAL INFECTION; ENTEROCOCCUS FAECALIS; FEMALE; INFECTION PREVENTION; MICROBIAL MORPHOLOGY; MOUSE; NONHUMAN; OPSONIZATION; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; STAPHYLOCOCCAL BACTEREMIA; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; STREPTOCOCCUS AGALACTIAE;

ADULT; ANIMALS; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACTEREMIA; DISEASE MODELS, ANIMAL; ENTEROCOCCUS FAECALIS; FEMALE; GLYCEROPHOSPHATES; HUMAN EXPERIMENTATION; HUMANS; IMMUNIZATION, PASSIVE; LIPOPOLYSACCHARIDES; MICE; MICE, INBRED BALB C; OPSONIN PROTEINS; PERITONITIS; PHAGOCYTOSIS; RABBITS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; STREPTOCOCCUS AGALACTIAE; SURVIVAL ANALYSIS; TEICHOIC ACIDS;

EID: 84858224547     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jis022     Document Type: Article

References (48)

1. McBride SM, Fischetti VA, Leblanc DJ, Moellering RC Jr, Gilmore MS. Genetic diversity among Enterococcus faecalis. PLoS One 2007; 2:e582.
2. Theilacker C, Kaczynski Z, Kropec A, et al. Opsonic antibodies to Enterococcus faecalis strain 12030 are directed against lipoteichoic acid. Infect Immun 2006; 74:5703-12. (Pubitemid 44484554)
3. Theilacker C, Kaczynski Z, Kropec A, et al. Serodiversity of opsonic antibodies against Enterococcus faecalis-glycans of the cell wall revisited. PLoS One 2011; 6:e17839.
4. Huebner J, Quaas A, Krueger WA, Goldmann DA, Pier GB. Prophylactic and therapeutic efficacy of antibodies to a capsular polysaccharide shared among vancomycin-sensitive and -resistant enterococci. Infect Immun 2000; 68:4631-6. (Pubitemid 30497734)
5. Neuhaus FC, Baddiley J. A continuum of anionic charge: structures and functions of D-alanyl-teichoic acids in gram-positive bacteria. Microbiol Mol Biol Rev 2003; 67:686-723. (Pubitemid 37549774)
6. Weidenmaier C, Peschel A. Teichoic acids and related cell-wall glycopolymers in gram-positive physiology and host interactions. Nat Rev Microbiol 2008; 6:276-87. (Pubitemid 351404772)
7. Fischer W. Bacterial phosphoglycolipids and lipoteichoic acids. In: Hanahan DJ, ed. Handbook of lipid research. Vol 6. New York: Plenum Press, 1990; 123-234.
8. Greenberg JW, Fischer W, Joiner KA. Influence of lipoteichoic acid structure on recognition by the macrophage scavenger receptor. Infect Immun 1996; 64:3318-25. (Pubitemid 26256182)
9. Henneke P, Morath S, Uematsu S, et al. Role of lipoteichoic acid in the phagocyte response to group B streptococcus. J Immunol 2005; 174: 6449-55. (Pubitemid 40663839)
10. Morath S, Geyer A, Hartung T. Structure-function relationship of cytokine induction by lipoteichoic acid from Staphylococcus aureus. J Exp Med 2001; 193:393-7. (Pubitemid 32524522)
11. Grundling A, Schneewind O. Synthesis of glycerol phosphate lipoteichoic acid in Staphylococcus aureus. Proc Natl Acad Sci U S A 2007; 104:8478-83. (Pubitemid 47175513)
12. Huebner J, Wang Y, Krueger WA, et al. Isolation and chemical characterization of a capsular polysaccharide antigen shared by clinical isolates of Enterococcus faecalis and vancomycin-resistant Enterococcus faecium. Infect Immun 1999; 67:1213-9. (Pubitemid 29108497)
13. Maekawa S, Yoshioka M, Kumamoto Y. Proposal of a new scheme for the serological typing of Enterococcus faecalis strains. Microbiol Immunol 1992; 36:671-81.
14. Jacob AE, Hobbs SJ. Conjugal transfer of plasmid-borne multiple antibiotic resistance in Streptococcus faecalis var. zymogenes. J Bacteriol 1974; 117:360-72.
15. Daneo-Moore L, Higgins ML. Morphokinetic reaction of Streptococcus faecalis (ATCC 9790) cells to the specific inhibition of macromolecular synthesis: nucleoid condensation on the inhibition of protein synthesis. J Bacteriol 1972; 109:1210-20.
16. Poyart C, Lamy MC, Boumaila C, Fiedler F, Trieu-Cuot P. Regulation of D-alanyl-lipoteichoic acid biosynthesis in Streptococcus agalactiae involves a novel two-component regulatory system. J Bacteriol 2001; 183:6324-34. (Pubitemid 34059406)
17. Poyart C, Pellegrini E, Gaillot O, Boumaila C, Baptista M, Trieu-Cuot P. Contribution of Mn-cofactored superoxide dismutase (SodA) to the virulence of Streptococcus agalactiae. Infect Immun 2001; 69:5098-106. (Pubitemid 32674496)
18. Iordanescu S, Surdeanu M. Two restriction and modification systems in Staphylococcus aureus NCTC8325. J Gen Microbiol 1976; 96:277-81.
19. Kreiswirth BN, Lofdahl S, Betley MJ, et al. The toxic shock syndrome exotoxin structural gene is not detectably transmitted by a prophage. Nature 1983; 305:709-12. (Pubitemid 13021519)
20. Duthie ES, Lorenz LL. Staphylococcal coagulase; mode of action and antigenicity. J Gen Microbiol 1952; 6:95-107.
21. Pohlmann-Dietze P, Ulrich M, Kiser KB, et al. Adherence of Staphylococcus aureus to endothelial cells: influence of capsular polysaccharide, global regulator agr, and bacterial growth phase. Infect Immun 2000; 68:4865-71.
22. Swenson JM, Spargo J, Tenover FC, Ferraro MJ. Optimal inoculation methods and quality control for the NCCLS oxacillin agar screen test for detection of oxacillin resistance in Staphylococcus aureus. J Clin Microbiol 2001; 39:3781-4. (Pubitemid 32954547)
23. Gill SR, Fouts DE, Archer GL, et al. Insights on evolution of virulence and resistance from the complete genome analysis of an early methicillin-resistant Staphylococcus aureus strain and a biofilm-producing methicillin-resistant Staphylococcus epidermidis strain. J Bacteriol 2005; 187:2426-38. (Pubitemid 40389140)
24. Muller E, Hubner J, Gutierrez N, Takeda S, Goldmann DA, Pier GB. Isolation and characterization of transposon mutants of Staphylococcus epidermidis deficient in capsular polysaccharide/adhesin and slime. Infect Immun 1993; 61:551-8. (Pubitemid 23030843)
25. Hancock LE, Gilmore MS. The capsular polysaccharide of Enterococcus faecalis and its relationship to other polysaccharides in the cell wall. Proc Natl Acad Sci U S A 2002; 99:1574-9. (Pubitemid 34136534)
26. Theilacker C, Coleman FT, Grout M, Wang J, Pier GB. Construction, characterization, and evaluation of immunogenicity and generation of opsonic antibody against mucoid Pseudomonas aeruginosa by acetylated seaweed-alginate conjugate and MEP conjugate vaccines. In: 101 American Society of Microbiology General Meeting. Orlando, FL, 2001.
27. Kropec A, Maira-Litran T, Jefferson KK, et al. Poly-N-acetylglucosamine production in Staphylococcus aureus is essential for virulence in murine models of systemic infection. Infect Immun 2005; 73:6868-76. (Pubitemid 41368855)
28. Maira-Litran T, Kropec A, Goldmann DA, Pier GB. Comparative opsonic and protective activities of Staphylococcus aureus conjugate vaccines containing native or deacetylated staphylococcal poly-N-acetyl-beta-(1-6)-glucosamine. Infect Immun 2005; 73: 6752-62. (Pubitemid 41368842)
29. Gening ML, Maira-Litran T, Kropec A, et al. Synthetic {beta}-(1->6)- linked N-acetylated and nonacetylated oligoglucosamines used to produce conjugate vaccines for bacterial pathogens. Infect Immun 2010; 78:764-72.
30. Hogendorf WF, Bos LJ, Overkleeft HS, Codee JD, Marel GA. Synthesis of an alpha-kojibiosyl substituted glycerol teichoic acid hexamer. Bioorg Med Chem 2010; 18:3668-78.
31. O'Riordan K, Lee JC. Staphylococcus aureus capsular polysaccharides. Clin Microbiol Rev 2004; 17:218-34. (Pubitemid 38120935)
32. Gross M, Cramton SE, Götz F, Peschel A. Key role of teichoic acid net charge in Staphylococcus aureus colonization of artificial surfaces. Infect Immun 2001; 69:3423-6. (Pubitemid 32332242)
33. Dunne DW, Resnick D, Greenberg J, Krieger M, Joiner KA. The type I macrophage scavenger receptor binds to gram-positive bacteria and recognizes lipoteichoic acid. Proc Natl Acad Sci U S A 1994; 91:1863-7. (Pubitemid 24080306)
34. Poutrel B, Rainard P, Sarradin P. Heterogeneity of cell-associated CP5 expression on Staphylococcus aureus strains demonstrated by flow cytometry. Clin Diagn Lab Immunol 1997; 4:275-8. (Pubitemid 27239684)
35. Goldenberg HB, McCool TL, Weiser JN. Cross-reactivity of human immunoglobulin G2 recognizing phosphorylcholine and evidence for protection against major bacterial pathogens of the human respiratory tract. J Infect Dis 2004; 190:1254-63. (Pubitemid 39287751)
36. Daniels CC, Briles TC, Mirza S, Hakansson AP, Briles DE. Capsule does not block antibody binding to PspA, a surface virulence protein of Streptococcus pneumoniae. Microb Pathog 2006; 40:228-33.
37. Dale JB, Baird RW, Courtney HS, Hasty DL, Bronze MS. Passive protection of mice against group A streptococcal pharyngeal infection by lipoteichoic acid. J Infect Dis 1994; 169:319-23. (Pubitemid 24045590)
38. Weisman LE, Thackray HM, Garcia-Prats JA, et al. Phase 1/2 double-blind, placebo-controlled, dose escalation, safety, and pharmacokinetic study of pagibaximab (BSYX-A110), an antistaphylococcal monoclonal antibody for the prevention of staphylococcal bloodstream infections, in very-low-birth-weight neonates. Antimicrob Agents Chemother 2009; 53:2879-86.
39. Weisman LE, Fischer GW, Thackray HM, et al. Safety and pharmacokinetics of a chimerized anti-lipoteichoic acid monoclonal antibody in healthy adults. Int Immunopharmacol 2009; 9:639-44.
40. Hufnagel M, Kropec A, Theilacker C, Huebner J. Naturally acquired antibodies against four Enterococcus faecalis capsular polysaccharides in healthy human sera. Clin Diagn Lab Immunol 2005; 12:930-4.
41. Romero-Steiner S, Musher DM, Cetron MS, et al. Reduction in functional antibody activity against Streptococcus pneumoniae in vaccinated elderly individuals highly correlates with decreased IgG antibody avidity. Clin Infect Dis 1999; 29:281-8. (Pubitemid 29380185)
42. Kelly-Quintos C, Kropec A, Briggs S, Ordonez CL, Goldmann DA, Pier GB. The role of epitope specificity in the human opsonic antibody response to the staphylococcal surface polysaccharide poly N-acetyl glucosamine. J Infect Dis 2005; 192:2012-19. (Pubitemid 41681901)
43. Theilacker C, Coleman FT, Mueschenborn S, Llosa N, Grout M, Pier GB. Construction and characterization of a Pseudomonas aeruginosa mucoid exopolysaccharide-alginate conjugate vaccine. Infect Immun 2003; 71:3875-84. (Pubitemid 36763514)
44. Kayhty H, Karanko V, Peltola H, Makela PH. Serum antibodies after vaccination with Haemophilus influenzae type b capsular polysaccharide and responses to reimmunization: no evidence of immunologic tolerance or memory. Pediatrics 1984; 74:857-65. (Pubitemid 15203456)
45. Lee YK, Mazmanian SK. Has the microbiota played a critical role in the evolution of the adaptive immune system? Science 2010; 330:1768-73.
46. Jarchum I, Pamer EG. Regulation of innate and adaptive immunity by the commensal microbiota. Curr Opin Immunol 2011; 23:353-60.
47. Poolman J, Borrow R. Hyporesponsiveness and its clinical implications after vaccination with polysaccharide or glycoconjugate vaccines. Expert Rev Vaccines 2011; 10:307-22.
48. Weisman LE, Thackray HM, Steinhorn RH, Walsh WF, Lassiter HA, Dhanireddy R, et al. A randomized study of a monoclonal antibody (pagibaximab) to prevent staphylococcal sepsis. Pediatrics. 2011; 128:271-9.